Psoriatic Arthritis News

Patients with rheumatoid arthritis who receive TNF inhibitors are more likely to develop psoriasis vs. those treated with methotrexate, according to an analysis of more than 880,000 post-marketing reports published in Scientific Reports.

The first 10 drugs eligible for price negotiation through Medicare includes etanercept and ustekinumab, biologic therapies commonly used to treat patients with rheumatic diseases, the Biden administration announced.

HHS announced the first 10 drugs that will be subject to Medicare price negotiations.

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.

Age, disease duration and sex are factors that may predict how likely a patient with psoriatic arthritis may be to enter remission following therapy with a TNF inhibitor, according to data published in Rheumatology.

Among patients with psoriasis, arthralgia should be considered a risk factor predicting progression to psoriatic arthritis, according to new EULAR points to consider for suspicious features in early PsA development.

Patients with axial spondyloarthritis and psoriatic arthritis routinely “bounce” from one provider to the next for years before finally receiving the correct diagnosis in a rheumatology clinic, according to experts.

The overwhelming majority of rheumatology practices have no formal policy for transitioning pediatric patients to adult care, according to a presenter at the 2023 AWIR annual conference.

The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.

AUSTIN, Texas — Communication and awareness of the myriad disease domains are essential to preventing a misdiagnosis of psoriatic arthritis, according to a presenter at the 2023 Rheumatology Nurses Society annual conference.